Ovarian Cancer

The phase 3 FLAMES trial results demonstrated an improvement in progression-free survival with senaparib monotherapy vs placebo, regardless of patient subgroup, in patients with newly diagnosed, advanced ovarian cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Leslie M. Randall, MD, MAS, evaluated the outcomes of the PRIMA/ENGOT-OV26/GOG-3012 study of niraparib as primary maintenance therapy for patients with ovarian cancer.

The addition of PARP inhibitors for the treatment of patients with BRCA-mutated advanced ovarian cancer has provided clinicians with a stronger set of treatment options. Looking at how the BRCA mutation responds to these inhibitors is then vital to deciding the patient’s treatment path.

The fast track designation for AVB-001 granted by the FDA recognizes its potential as a treatment option for patients with relapsed/refractory ovarian cancer.

Results of the phase 3 MIRASOL study evaluating mirvetuximab soravtansine for platinum-resistant ovarian cancer will be announced at an upcoming meeting.

Findings from a phase 1 support the fast track designation given by the FDA to IDE161, a potent, selective, small-molecule inhibitor of PARG, for patients with BRCA1/2 mutant ovarian cancer.

In an interview Targeted Oncology, Christina Fotopoulou, MD, PhD, discussed the background and results of 3 studies for patients with ovarian cancer.

The primary end point was not met in the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of tumor treating fields therapy plus paclitaxel in patients with platinum-resistant ovarian cancer.

Barbara Buttin, MD, discusses the PAOLA-1 clinical trial and it impact on the first-line treatment of ovarian cancer.

Chad A. Hamilton, MD, offers closing thoughts on the future outlook and unmet needs in the ovarian cancer treatment landscape.

Key takeaways from recent data updates from the PRIMA and PAOLA-1 trials investigating PARP inhibitors in ovarian cancer.

Chad A. Hamilton, MD, shares strategies for managing gastrointestinal toxicities and fatigue for patients receiving PARP inhibitors for the treatment of ovarian cancer.

Clinical insights on adverse effects seen with PARP inhibitors in the treatment of patients with ovarian cancer.

An overview of factors that influence the initiation of maintenance therapy for patients with ovarian cancer.

Chad A. Hamilton, MD, discusses how clinical trial data inform treatment selection for patients with ovarian cancer.

A comprehensive overview of the maintenance therapy landscape in ovarian cancer, with a focus on clinical trials investigating bevacizumab, olaparib, and niraparib.

An expert gynecologic oncologist reviews guideline recommendations for molecular testing in ovarian cancer and shares his testing practices.

Chad A. Hamilton, MD, presents the case of a 49-year-old woman with BRCA wild-type ovarian cancer and offers his initial impressions.

Barbara Buttin, MD, provided insight on the phase 3 DUO-O trial and what it implies for the future of ovarian cancer treatment.

In an interview with Targeted Oncology, Barbara Buttin, MD, discussed important ovarian cancer research for which results were presented during the 2023 ASCO Annual Meeting.

There was no difference in the risk of disease progression or death outcomes noted between patients with ovarian cancer treated with batiraxcept and paclitaxel vs batiraxcept alone in the AXLerate-OC trial.

Topline results reported from the UPLIFT trial showed it did not meet its primary end point of objective response rate in the NaPi2b-positive population with ovarian cancer.

During a Targeted Oncology™ Clinical Case Forum™ event, Lyndsay Willmott, MD, discussed the data supporting the use of PARP inhibitors as primary maintenance therapy for patients with ovarian cancer.

Niraparib as a monotherapy is supported as standard of care for a broad patient population with advanced ovarian cancer after first-line platinum-based chemotherapy.

Christina Fotopoulou, MD, PhD, discusses the results of the DUO-O trial in patients with newly diagnosed ovarian cancer.